• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Xenon Pharmaceuticals Inc.

    12/1/25 4:11:56 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XENE alert in real time by email
    S-8 1 xene-20251201.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on December 1, 2025

    Registration Statement No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    THE SECURITIES ACT OF 1933

     

    XENON PHARMACEUTICALS INC.

    (Exact name of registrant as specified in its charter)

     

    Canada

    98-0661854

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    3650 Gilmore Way

    Burnaby, British Columbia V5G 4W8
    Canada

    (Address of principal executive offices, including zip code)

    Amended and Restated 2025 Inducement Equity Incentive Plan

    (Full title of the plan)

    Thomas P. Kelly

    Chief Financial Officer

    Xenon Pharmaceuticals Inc.

    3650 Gilmore Way

    Burnaby, British Columbia V5G 4W8

    Canada
    (Name and address of agent for service)

    (604) 484-3300

    (Telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☒

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

     

     

     

     

     

     

     

    Emerging growth company

     

    ☐

     

     

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     


     

     

    TABLE OF CONTENTS

     

    Page

    Item 3. Incorporation of Documents by Reference

    1

    Item 8. Exhibits

    2

    Signatures

     

     


     

    EXPLANATORY NOTE

    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    This registration statement on Form S-8 (the “Registration Statement”) registers an additional 125,000 common shares, without par value, of Xenon Pharmaceuticals Inc. (the “Registrant”) to be issued pursuant to the Registrant’s Amended and Restated 2025 Inducement Equity Incentive Plan. Accordingly, the contents of the Registration Statement on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on February 27, 2025 (File No. 333-285382) (the "Previous Form S-8"), including periodic and other reports that the Registrant filed after the filing of the Previous Form S-8 to maintain current information about the Registrant, are incorporated herein by reference into this Registration Statement pursuant to General Instruction E to Form S-8.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents previously filed with the U.S. Securities and Exchange Commission (the "Commission") are hereby incorporated by reference:

    (1)
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025;
    (2)
    All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Act”), since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (1) above; and
    (3)
    The description of the Registrant’s common shares contained in the Registration Statement on Form 8-A12B (File No. 001-36687) filed with the Commission on October 10, 2014, pursuant to Section 12(b) of the Act, as updated by any amendment or report filed for the purpose of updating such description, including the description of the Registrant’s Common Shares contained in Exhibit 4.3 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed on February 27, 2025.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Act, prior to the filing of a post-effective amendment which indicates that all securities registered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information furnished under items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    -1-


     

    Item 8. Exhibits

     

    Exhibit
    Number

     

    Description of Document

     

    Incorporated by Reference

     

     

     

     

    Form

     

    File No.

     

    Exhibit

     

    Filing Date

     

     

     

     

     

     

     

     

     

     

     

    4.1

     

    Specimen common share certificate of the Registrant.

     

    S-1/A

     

    333-198666

     

    4.1

     

    10/6/2014

     

     

     

     

     

     

     

     

     

     

     

    4.2+

     

    Amended and Restated 2025 Inducement Equity Incentive Plan and related form agreements.

     

    8-K

     

    001-36687

     

    10.1

     

    12/1/2025

     

     

     

     

     

     

     

     

     

     

     

    5.1

     

    Opinion of Blake, Cassels & Graydon LLP.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.1

     

    Consent of KPMG LLP, Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.2

     

    Consent of Blake, Cassels & Graydon LLP (contained in Exhibit 5.1 hereto).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    24.1

     

    Power of Attorney (contained on signature page hereto).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    107

     

    Filing Fee Table

     

     

     

     

     

     

     

     

     

    + Indicates management contract or compensatory plan, contract or arrangement.

     


     

    -2-


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Needham Heights, Massachusetts, on December 1, 2025.

     

    XENON PHARMACEUTICALS INC.

     

    By:

    /s/ Thomas P. Kelly

    Thomas P. Kelly

    Chief Financial Officer

     

     


     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ian Mortimer and Thomas P. Kelly as his and her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities (including his or her capacity as a director and/or officer of Xenon Pharmaceuticals Inc.) to sign any or all amendments (including post-effective amendments) to this registration statement on Form S-8, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
     

    Name

    Title

    Date

     

     

     

     

     

    /s/ Ian Mortimer

    President, Chief Executive Officer and Director (Principal Executive Officer)

    December 1, 2025

    Ian Mortimer

     

    /s/ Thomas P. Kelly

    Chief Financial Officer (Principal Financial and Accounting Officer)

    December 1, 2025

    Thomas P. Kelly

    /s/ Dawn Svoronos

    Chair of the Board of Directors

    December 1, 2025

    Dawn Svoronos

    /s/ Gillian Cannon

    Director

    December 1, 2025

    Gillian Cannon

    /s/ Steven Gannon

    Director

    December 1, 2025

    Steven Gannon

    /s/ Elizabeth Garofalo

    Director

    December 1, 2025

    Elizabeth Garofalo

    /s/ Justin Gover

    Director

    December 1, 2025

    Justin Gover

    /s/ Patrick Machado

    Director

    December 1, 2025

    Patrick Machado

     

    /s/ Gary Patou

    Director

    December 1, 2025

    Gary Patou

     

     


    Get the next $XENE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XENE

    DatePrice TargetRatingAnalyst
    9/3/2025$48.00Overweight
    Wells Fargo
    5/7/2025$55.00Buy
    Chardan Capital Markets
    2/11/2025$67.00Buy
    Deutsche Bank
    10/10/2024$50.00Outperform
    Raymond James
    10/1/2024$53.00Buy
    H.C. Wainwright
    1/4/2024$62.00Buy
    Citigroup
    12/8/2023$63.00Outperform
    Robert W. Baird
    10/24/2023Overweight
    Cantor Fitzgerald
    More analyst ratings

    $XENE
    SEC Filings

    View All

    SEC Form 144 filed by Xenon Pharmaceuticals Inc.

    144 - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    12/8/25 5:10:33 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Xenon Pharmaceuticals Inc.

    S-8 - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

    12/1/25 4:11:56 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

    12/1/25 4:05:34 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

    Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedomNew X-TOLE OLE data analysis supports the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner, even in patients with difficult-to-treat diseaseFour real-world study posters illustrate significant burden of depression and ASM titration on people living with epilepsy; poster on impact of depression on outcomes and treatment patterns in patients with newly diagnosed epilepsy highlighted in AES press programNew pre-clinical data in Dravet syndrome suggest potential to improve motor function through NaV1.

    12/5/25 9:00:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 39,250 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of December 4, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasd

    12/4/25 5:20:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

    VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its data presentations at the American Epilepsy Society Annual Meeting (AES 2025), including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in focal onset seizures (FOS) and real world study data on the impact of depression and burden of titration in epilepsy. The webinar will also include an upd

    12/3/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Mortimer Ian sold $1,142,513 worth of shares (25,205 units at $45.33), decreasing direct ownership by 81% to 6,000 units (SEC Form 4)

    4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    12/9/25 7:40:08 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT & CEO Mortimer Ian sold $4,366 worth of shares (97 units at $45.01), decreasing direct ownership by 0.31% to 31,205 units (SEC Form 4)

    4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    12/3/25 8:20:44 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Kelly Thomas Patrick

    4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    10/17/25 6:43:47 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo resumed coverage on Xenon Pharmaceuticals with a new price target

    Wells Fargo resumed coverage of Xenon Pharmaceuticals with a rating of Overweight and set a new price target of $48.00

    9/3/25 8:41:10 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Xenon Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $55.00

    5/7/25 8:39:12 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank initiated coverage on Xenon Pharmaceuticals with a new price target

    Deutsche Bank initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $67.00

    2/11/25 7:18:40 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc.

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    11/12/24 10:40:28 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    2/14/24 9:12:03 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    2/14/24 7:43:11 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Leadership Updates

    Live Leadership Updates

    View All

    Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

    VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced the appointment of Tucker Kelly as Chief Financial Officer (CFO) and member of the Xenon senior executive team. Mr. Kelly is a proven executive who brings extensive strategic and commercial finance expertise, both in the U.S. and internationally, that will help the Company prepare for the anticipated commercialization of its lead candidate, azetukalner. Azetukalner is currently being studi

    10/16/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

    VANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Darren Cline as Chief Commercial Officer and member of the Xenon senior executive team. In this role, Mr. Cline will lead commercial strategy and operations for the Company's portfolio of product and development candidates, with initial focus on its lead Phase 3 candidate, azetukalner, and first potential launch in epilepsy. Azetukalner is currently being studied in Phase 3 trials for the trea

    6/24/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

    – OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner – Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer – Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36 – Patient-reported survey data and literature review illustrate significant mental health and comorbidity burdens of focal onset seizures highlighting areas of unmet need for people living with epilepsy – New pre-clinical data shows Nav1.1 potentiator provides protection against

    12/6/24 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Financials

    Live finance-specific insights

    View All

    Xenon Reports Third Quarter 2025 Financial Results & Business Update

    – Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing thera

    11/3/25 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon to Report Q3 2025 Financial Results on November 3, 2025

    VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, November 3, 2025. Conference Call/Webcast Information: Date:Monday, November 3, 2025  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference I

    10/27/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Reports Second Quarter 2025 Financial Results & Business Update

    – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializ

    8/11/25 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care